Tc 99m oregovomab

N/A

Report date: 2025/11/24 17:27:48

Base Information

Drug NameTc 99m oregovomab

Drug Alias NameMAb B43.13-Tc 99mTru-Scint-AGTru-Scint-OVMonoclonal antibody B43.13-technetium-99m

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive diagnostic agent +[6]

Mechanisms of ActionRadionuclide imaging enhancersMucin-16 inhibitors

TargetsMucin-16

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiomira

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiomira

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A